References
1. Neunert C, Terrell DR, Arnold DM, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv . 2019;3(23):3829-3866. doi:10.1182/BLOODADVANCES.2019000966
2. Provan D, Arnold DM, Bussel JB, et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv . 2019;3(22):3780-3817. doi:10.1182/BLOODADVANCES.2019000812
3. Jayabose S, Levendoglu-Tugal O, Ozkaynkak MF, Visintainer P, Sandoval C. Long-term outcome of chronic idiopathic thrombocytopenic purpura in children. J Pediatr Hematol Oncol . 2004;26(11):724-726. doi:10.1097/00043426-200411000-00007
4. Terrell DR, Neunert CE, Cooper N, et al. Immune Thrombocytopenia (ITP): Current Limitations in Patient Management. Medicina (Kaunas) . 2020;56(12):1-10. doi:10.3390/MEDICINA56120667
5. Djulbegovic B, Cohen Y, Portielje JEA, Westendorp RGJ, Kluin-Nelemans HC, Brand A. The natural history of refractory idiopathic thrombocytopenic purpura. Blood . 2001;98(7):2282-2283. doi:10.1182/BLOOD.V98.7.2282
6. Bramer WM, de Jonge GB, Rethlefsen ML, Mast F, Kleijnen J. A systematic approach to searching: an efficient and complete method to develop literature searches. J Med Libr Assoc . 2018;106(4):531-541. doi:10.5195/JMLA.2018.283
7. Nama N, Barrowman N, O’Hearn K, Sampson M, Zemek R, McNally JD. Quality control for crowdsourcing citation screening: the importance of assessment number and qualification set size. J Clin Epidemiol . 2020;122:160-162. doi:10.1016/J.JCLINEPI.2020.02.009
8. Khera S, Pramanik SK, Yanamandra U, Mishra K, Kapoor R, Das S. Dapsone: An Old but Effective Therapy in Pediatric Refractory Immune Thrombocytopenia. Indian J Hematol Blood Transfus . 2020;36(4):690-694. doi:10.1007/S12288-020-01286-9
9. Ay Y, Karapinar TH, Oymak Y, et al. Retrospective analysis of rituximab therapy and splenectomy in childhood chronic and refractory immune thrombocytopenic purpura. Blood Coagul Fibrinolysis . 2016;27(4):431-435. doi:10.1097/MBC.0000000000000488
10. Leblebisatan G, Kilinc Y, Cil M, Sasmaz İ, Ozkan A. Eltrombopag For Immune Thrombocytopenic Children in a Single Region. Indian J Hematol Blood Transfus . 2018;34(4):707-710. doi:10.1007/S12288-018-0928-Y
11. Sezgin Evim M, Baytan B, Güneş AM. Childhood Immune Thrombocytopenia: Long-term Follow-up Data Evaluated by the Criteria of the International Working Group on Immune Thrombocytopenic Purpura.Turkish J Haematol Off J Turkish Soc Haematol . 2014;31(1):32-39. doi:10.4274/TJH.2012.0049
12. Adly AAM, Ragab IA, Ismail EAR, Farahat MM. Evaluation of the immature platelet fraction in the diagnosis and prognosis of childhood immune thrombocytopenia. Platelets . 2015;26(7):645-650. doi:10.3109/09537104.2014.969220
13. Matsubara K, Takahashi Y, Hayakawa A, et al. Long-term follow-up of children with refractory immune thrombocytopenia treated with rituximab.Int J Hematol . 2014;99(4):429-436. doi:10.1007/S12185-014-1541-Y
14. Pasquet M, Aladjidi N, Guiton C, et al. Romiplostim in children with chronic immune thrombocytopenia (ITP): the French experience. Br J Haematol . 2014;164(2):266-271. doi:10.1111/BJH.12609
15. Grace RF, Long M, Kalish LA, Neufeld EJ. Applicability of 2009 international consensus terminology and criteria for immune thrombocytopenia to a clinical pediatric population. Pediatr Blood Cancer . 2012;58(2):216-220. doi:10.1002/PBC.23112
16. Rao VK, Price S, Perkins K, et al. Use of rituximab for refractory cytopenias associated with autoimmune lymphoproliferative syndrome (ALPS). Pediatr Blood Cancer . 2009;52(7):847-852. doi:10.1002/PBC.21965
17. Parodi E, Rivetti E, Amendola G, et al. Long-term follow-up analysis after rituximab therapy in children with refractory symptomatic ITP: identification of factors predictive of a sustained response. Br J Haematol . 2009;144(4):552-558. doi:10.1111/J.1365-2141.2008.07487.X
18. Rao A, Kelly M, Musselman M, et al. Safety, efficacy, and immune reconstitution after rituximab therapy in pediatric patients with chronic or refractory hematologic autoimmune cytopenias. Pediatr Blood Cancer . 2008;50(4):822-825. doi:10.1002/PBC.21264
19. Oved JH, Lee CSY, Bussel JB. Treatment of Children with Persistent and Chronic Idiopathic Thrombocytopenic Purpura: 4 Infusions of Rituximab and Three 4-Day Cycles of Dexamethasone. J Pediatr . 2017;191:225-231. doi:10.1016/J.JPEDS.2017.08.036
20. Grace RF, Bennett CM, Ritchey AK, et al. Response to steroids predicts response to rituximab in pediatric chronic immune thrombocytopenia. Pediatr Blood Cancer . 2012;58(2):221-225. doi:10.1002/PBC.23130
21. Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood . 2009;113(11):2386-2393. doi:10.1182/BLOOD-2008-07-162503
22. Gupta N, Kavuru S, Patel D, et al. Rituximab-based chemotherapy for steroid-refractory autoimmune hemolytic anemia of chronic lymphocytic leukemia. Leukemia . 2002;16(10):2092-2095. doi:10.1038/SJ.LEU.2402676
23. Paludo J, Abeykoon JP, Kumar S, et al. Dexamethasone, rituximab and cyclophosphamide for relapsed and/or refractory and treatment-naïve patients with Waldenstrom macroglobulinemia. Br J Haematol . 2017;179(1):98-105. doi:10.1111/BJH.14826
24. Rodrigo C, Gooneratne L. Dapsone for primary immune thrombocytopenia in adults and children: an evidence-based review. J Thromb Haemost . 2013;11(11):1946-1953. doi:10.1111/JTH.12371
25. Godeau B, Durand JM, Roudot-Thoraval F, et al. Dapsone for chronic autoimmune thrombocytopenic purpura: a report of 66 cases. Br J Haematol . 1997;97(2):336-339. doi:10.1046/J.1365-2141.1997.412687.X
26. Oo T, Hill QA. Disappointing response to dapsone as second line therapy for primary ITP: a case series. Ann Hematol . 2015;94(6):1053-1054. doi:10.1007/S00277-014-2285-8
27. Patel AP, Patil AS. Dapsone for immune thrombocytopenic purpura in children and adults. Platelets . 2015;26(2):164-167. doi:10.3109/09537104.2014.886677
28. Damodar S, Viswabandya A, George B, Mathews V, Chandy M, Srivastava A. Dapsone for chronic idiopathic thrombocytopenic purpura in children and adults–a report on 90 patients. Eur J Haematol . 2005;75(4):328-331. doi:10.1111/J.1600-0609.2005.00545.X
29. Cuker A, Neunert CE. How I treat refractory immune thrombocytopenia.Blood . 2016;128(12):1547-1554. doi:10.1182/BLOOD-2016-03-603365
30. Amgen In. NPLATE® (romiplostim) for injection, for subcutaneous use [prescribing information]. Published online 2018.
31. Corporation NP. PROMACTA® (eltrombopag) tablets, for oral use; PROMACTA® (eltrombopag) for oral suspension [prescribing information]. :2018.
32. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71. doi: 10.1136/bmj.n71
Appendix A. Electronic search strategies
Note: Note: Searches were conducted using an Ovid multi-database search and duplicate records were removed online giving preference to MEDLINE, then Embase, with no field preference. Lines 1-18 are optimized for MEDLINE. Lines 19-37 are optimized for Embase and lines 38-56 are optimized for CENTRAL. The next lines isolate the records to the database the search was designed for, combine those sets and then remove duplicate records and final isolate the records from each database again so each can be downloaded and imported into the citation manager using a database-specific import filter.
1. Purpura, Thrombocytopenic, Idiopathic/ or (ITP or Immune thrombocytopen* or autoimmune thrombocytopen* or idiopathic thrombocytopen* or werlhof*).ti,ab,kf.
2. (thrombocytopenia and (Evans or immune dysregulation or ALPS or CTLA4 or SLE or CVID)).mp.
3. inherited thrombocytopenia.ti,ab,kf.
4. (thrombocytopenia and inherited marrow failure).ti,ab,kf.
5. 1 or 2 or 3 or 4
6. (refractory or intractable or treatment-resistant or treatment failure* or steroid-dependent or second line or chronic*).ti,ab,kf.
7. (child* or adolesc* or infan* or pediatr* or paediatr*).mp.
8. Terminology as Topic/ or (terminology or nomenclature or definition or criteria or classification).mp.
9. Purpura, Thrombocytopenic, Idiopathic/di or (diagnosis or diagnostic or workup or work-up).ti,ab,kf.
10. Purpura, Thrombocytopenic, Idiopathic/dh, dt, pc, rt, rh, th, cl
11. (therapy or therapeutics or treatment or management or intervention or Second line or novel or Rituximab or romiplostim or thrombopoietin-receptor agonists or immunosuppress* or glucocorticoid* or prednisone or dexamethasone or eltrombopag or Mycophenolate Mophetil or Mycophenolic acid or Azathioprine or Vincristine or vinblastine or Cyclophosphamide or autologous stem cell or dexamethasone or splenectomy*).mp.
12. 5 and 6 and 7 and (9 or 10 or 11)
13. 5 and 7 and 8
14. 12 or 13
15. limit 14 to yr=”2000 - 2021”
16. limit 15 to (english or french or german or polish or spanish)
17. limit 16 to (comment or editorial or letter)
18. 16 not 17
19. Idiopathic Thrombocytopenic Purpura/ or (ITP or Immune thrombocytopen* or autoimmune thrombocytopen* or idiopathic thrombocytopen* or werlhof*).ti,ab,kw.
20. (thrombocytopenia and (Evans or immune dysregulation or ALPS or CTLA4 or SLE or CVID)).mp.
21. inherited thrombocytopenia.ti,ab,kw.
22. (thrombocytopenia and inherited marrow failure).ti,ab,kw.
23. or/19-22
24. (refractory or intractable or treatment-resistant or treatment failure* or steroid-dependent or second line or chronic).ti,ab,kw.
25. (baby* or babies* or newborn* or infan* or neonat* or preschool* or pre-school* or child* or pediatr* or paediatr* or teen* or adolescen* or pediatr* or paediatr*).mp.
26. Nomenclature/ or (terminology or nomenclature or definition or criteria or classification).mp.
27. Idiopathic Thrombocytopenic Purpura/di or (diagnosis or diagnostic or workup or work-up).ti,ab,kw.
28. Idiopathic Thrombocytopenic Purpura/dt, pc, rt, rh, th, cl
29. (therapy or therapeutics or treatment or management or intervention or Second line or novel or Rituximab or romiplostim or thrombopoietin-receptor agonists or immunosuppress* or glucocorticoid* or prednisone or dexamethasone or eltrombopag or Mycophenolate Mophetil or Mycophenolic acid or Azathioprine or Vincristine or vinblastine or Cyclophosphamide or autologous stem cell or dexamethasone or splenectomy*).mp.
30. 23 and 24 and 25 and (27 or 28 or 29)
31. 23 and 25 and 26
32. 30 or 31
33. limit 32 to yr=”2000 - 2021”
34. limit 33 to (english or french or german or polish or spanish)
35. limit 34 to embase
36. limit 35 to (editorial or letter or ”review”)
37. 35 not 36
38. (ITP or Immune thrombocytopen* or autoimmune thrombocytopen* or idiopathic thrombocytopen* or werlhof*).ti,ab,kw.
39. (thrombocytopenia and (Evans or immune dysregulation or ALPS or CTLA4 or SLE or CVID)).mp.
40. (thrombocytopenia and inherited marrow failure).ti,ab,kw.
41. inherited thrombocytopenia.ti,ab,kw.
42. or/38-41
43. (refractory or intractable or treatment-resistant or treatment failure* or steroid-dependent or second line or chronic).ti,ab,kw.
44. (baby* or babies* or newborn* or infan* or neonat* or preschool* or pre-school* or child* or pediatr* or paediatr* or teen* or adolescen* or pediatr* or paediatr*).mp.
45. (terminology or nomenclature or definition or criteria or classification).mp.
46. (diagnosis or diagnostic or workup or work-up).ti,ab,kw.
47. (therapy or therapeutics or treatment or management or intervention or Second line or novel or Rituximab or romiplostim or thrombopoietin-receptor agonists or immunosuppress* or glucocorticoid* or prednisone or dexamethasone or eltrombopag or Mycophenolate Mophetil or Mycophenolic acid or Azathioprine or Vincristine or vinblastine or Cyclophosphamide or autologous stem cell or dexamethasone or splenectomy*).mp.
48. 42 and 43 and 44 and (46 or 47)
49. 42 and 44 and 45
50. 48 or 49
51. limit 50 to yr=”2000 - 2021”
52. 18 use medall
53. 37 use emczd
54. 51 use cctr
55. or/52-54
56. remove duplicates from 55
57. 56 use medall
58. 56 use emczd
59. 56 uce cctr